Lupin is currently trading at Rs. 778.45, up by 8.35 points or 1.08% from its previous closing of Rs. 770.10 on the BSE.
The scrip opened at Rs. 766.00 and has touched a high and low of Rs. 784.50 and Rs. 766.00 respectively. So far 48355 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1498.40 on 23-Mar-2017 and a 52 week low of Rs. 750.00 on 08-Mar-2018.
Last one week high and low of the scrip stood at Rs. 784.50 and Rs. 750.00 respectively. The current market cap of the company is Rs. 35239.38 crore.
The promoters holding in the company stood at 47.02%, while Institutions and Non-Institutions held 37.64% and 15.35% respectively.
Lupin has launched its Tydemy Tablets in United States having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Lupin’s Tydemy (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg) are the generic equivalents of Bayer HealthCare Pharmaceuticals Safyral tablets. It is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception.
Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg tablets, had annual sales of around $ 22 million in the US as per IQVIA January 2018.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.